It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Purpose
To compare different scoring systems for predicting in-hospital mortality in patients with Fournier gangrene (FG).
Methods
A comprehensive literature search was performed to find all scoring systems that have been proposed previously as a predictor for in-hospital mortality in patients with FG. Data of all patients with FG who were hospitalized in one of Indonesia’s largest tertiary referral hospitals between 2012 and 2022 were used. The receiver operating characteristic (ROC) curve analysis was performed to evaluate the diagnostic performance of the scoring systems.
Results
Ten scoring systems were found, i.e., Fournier’s Gangrene Severity Index (FGSI), Uludag FGSI, simplified FGSI, NUMUNE Fournier score (NFS), Laboratory Risk Indicator for Necrotizing Fasciitis, age-adjusted Charlson comorbidity index, sequential organ failure assessment (SOFA), quick SOFA, acute physiology and chronic health evaluation II, and surgery APGAR score (SAS). Of 164 FG patients included in the analyses, 26.4% died during hospitalization. All scoring systems except SAS could predict in-hospital mortality of patients with FG. Three scoring systems had areas under the ROC curve (AUROC) higher than 0.8, i.e., FGSI (AUROC 0.905, 95% confidence interval (CI) 0.860–0.950), SOFA (AUROC 0.830, 95% CI 0.815–0.921), and NFS (AUROC 0.823, 95% CI 0.739–0.906). Both FGSI and SOFA had sensitivity and NPV of 1.0, whereas NFS had a sensitivity of 0.74 and an NPV of 0.91.
Conclusion
This study shows that FGSI and SOFA are the most reliable scoring systems to predict in-hospital mortality in FG, as indicated by the high AUROC and perfect sensitivity and NPV.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 Universitas Airlangga-Dr. Soetomo General Academic Hospital, Department of Urology, Faculty of Medicine, Surabaya, Indonesia (GRID:grid.440745.6) (ISNI:0000 0001 0152 762X); University of Groningen, University Medical Center Groningen, Department of Health Sciences, Groningen, The Netherlands (GRID:grid.4494.d) (ISNI:0000 0000 9558 4598)
2 Faculty of Medicine Universitas Airlangga, Division of Pharmacology and Therapy, Department of Anatomy, Histology, and Pharmacology, Surabaya, Indonesia (GRID:grid.440745.6) (ISNI:0000 0001 0152 762X); University Medical Center Groningen, Division of Nephrology, Department of Internal Medicine, Groningen, The Netherlands (GRID:grid.4494.d) (ISNI:0000 0000 9558 4598)
3 Universitas Airlangga-Dr. Soetomo General Academic Hospital, Department of Urology, Faculty of Medicine, Surabaya, Indonesia (GRID:grid.440745.6) (ISNI:0000 0001 0152 762X)
4 Universitas Airlangga-Dr. Soetomo General Academic Hospital, Department of Clinical Pathology, Faculty of Medicine, Surabaya, Indonesia (GRID:grid.440745.6) (ISNI:0000 0001 0152 762X)
5 Mahidol University, Department of Immunology, Faculty of Medicine Siriraj Hospital, Bangkok, Thailand (GRID:grid.10223.32) (ISNI:0000 0004 1937 0490)
6 University Medical Center Groningen, Division of Nephrology, Department of Internal Medicine, Groningen, The Netherlands (GRID:grid.4494.d) (ISNI:0000 0000 9558 4598); Faculty of Medicine Universitas Airlangga, Department of Public Health and Preventive Medicine, Surabaya, Indonesia (GRID:grid.440745.6) (ISNI:0000 0001 0152 762X)
7 University of Groningen, University Medical Center Groningen, Department of Health Sciences, Groningen, The Netherlands (GRID:grid.4494.d) (ISNI:0000 0000 9558 4598); Faculty of Medicine Universitas Airlangga, Division of Pharmacology and Therapy, Department of Anatomy, Histology, and Pharmacology, Surabaya, Indonesia (GRID:grid.440745.6) (ISNI:0000 0001 0152 762X)
8 University of Groningen, University Medical Center Groningen, Department of Health Sciences, Groningen, The Netherlands (GRID:grid.4494.d) (ISNI:0000 0000 9558 4598); University Medical Center Groningen, University of Groningen, Institute of Science in Healthy Ageing and Healthcare (SHARE), Groningen, The Netherlands (GRID:grid.4830.f) (ISNI:0000 0004 0407 1981); University of Groningen, Unit of Pharmacotherapy, Epidemiology and Economics (PTE2), Department of Pharmacy, Groningen, The Netherlands (GRID:grid.4830.f) (ISNI:0000 0004 0407 1981); University of Groningen, Department of Economics, Econometrics and Finance, Faculty of Economics and Business, Groningen, The Netherlands (GRID:grid.4830.f) (ISNI:0000 0004 0407 1981)